Sino Biopharmaceutical Ltd. (SMZ1)

Overview

Sino Biopharmaceutical Limited, incorporated in 2000 and based in Wan Chai, Hong Kong, serves as an investment holding entity that leads the way in the pharmaceutical industry within the People's Republic of China. This conglomerate focuses on the research and development of new pharmaceutical solutions, operating across three main segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. Its diverse product portfolio is tailored to treat a range of conditions, including oncology, liver diseases, respiratory disorders, surgery/analgesia, and cardio-cerebral vascular diseases. Additionally, Sino Biopharmaceutical is engaged in long-term investments and extends its reach into the healthcare and hospital sector, striving to contribute to the overall advancement of China's medical and healthcare industry.

Products and Services

Sino Biopharmaceutical Limited offers a comprehensive array of medicines and healthcare solutions aimed at improving the quality of life for patients. Each product is the result of extensive research and dedication to innovation within the pharmaceutical field.

• Qingkeshu Tablets: A leading oncology medication designed to aid in the treatment of cancer. Its formulation is based on the latest research in cancer treatment and therapy.
• Focus V Capsules: Another innovative oncology product, these capsules are tailored for specific cancer treatments, underlining Sino Biopharmaceutical’s commitment to battling this pervasive disease.
• Annike Injection: Used in the field of oncology, this injectable form of medication supports cancer treatment protocols, offering another avenue for patient care.
• Anyue Capsules: Part of the company's oncology range, these capsules provide supportive care in cancer treatment regimens.
• Tianqing ganmei Injection: A liver disease medicine, showcasing the company’s dedication to treating a wide spectrum of liver conditions, improving patient outcomes.
• Runzhong Dispersible Tablets: These tablets are formulated for liver disease, providing an effective treatment option for conditions affecting the liver.
• Tianqing suchang Suspension for Inhalation: This respiratory system medicine offers a modern approach to treating respiratory conditions, allowing for improved breathing and quality of life.
• Tianyun for Injection: Another key product in the respiratory disease portfolio, this injectable medicine supports comprehensive respiratory care.
• Debaian Cataplasms: Used in surgery/analgesia, these cataplasms are designed to relieve pain, facilitating recovery and comfort during the postoperative period.
• Gaisanchun Soft Capsules: Offering relief and therapy in the surgery/analgesia segment, these capsules highlight the company’s focus on post-surgical care and pain management.
• Yilunping and Kaina Tablets: These cardio-cerebral vascular medicines represent Sino Biopharmaceutical's dedication to fighting cardiovascular diseases, offering patients hope and improved health outcomes.

Beyond these products, Sino Biopharmaceutical is continually exploring new treatments through its robust R&D efforts and maintains a significant presence in the healthcare and hospital business, serving as a cornerstone of its comprehensive approach to healthcare innovation and service.